A prodrug is a compound the body must change before it works. Psilocybin is described as “primarily a pro-drug” that alkaline phosphatase dephosphorylates to the active metabolite psilocin (Dinis-Oliveira, 2017). A 2025 systematic review describes the conversion as quick (Meshkat et al., 2025).
The animal and cell work fits. In a 2022 structure-activity study, compounds with a 4-hydroxy group, like psilocin, were more potent in cell assays than the phosphorylated forms like psilocybin, yet psilocybin still produced the head-twitch response in mice, consistent with the animal converting it (Glatfelter et al., 2022).
The word matters for reading research. Clinical trials give a measured dose of psilocybin, but it is psilocin that occupies brain receptors; a 2019 PET study found that psilocin levels in blood tracked the intensity of the experience (Madsen et al., 2019). Many medicines outside psychedelic research are prodrugs too. The term describes chemistry, not safety.
Sources
- Dinis-Oliveira, 2017, Drug Metabolism Reviews
- Meshkat et al., 2025, Pharmaceutics: systematic review
- Glatfelter et al., 2022, ACS Pharmacology & Translational Science
- Madsen et al., 2019, Neuropsychopharmacology
Last checked .